Seattle Genetics, Inc.

Seagen Inc.

Django Sussman

Patrick J Burke

Scott C Jeffrey

Brian E Toki

Dennis R Benjamin

Stephen C Alley

Lori Westendorf

Maureen Ryan

Paul J Carter

William Arthur

Maria Leia Smith

May Kung Sutherland

Albina Nesterova

Michael Feldhaus

Che-Leung Law

Charlotte McDonagh

Timothy S Lewis

Travis Biechele

Andrew Waight

Ana Kostic

Fu Li

Chris Leiske

Jocelyn Leiske

Charlotte Mcdonagh

Brian Toki

Toki Brian

The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.

Cysteine mutated antibodies for conjugation

The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.

BCMA antibodies and use of same to treat cancer and immunological disorders

Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.

Anti-NTB-A antibodies and related compositions and methods

The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.

Combination therapy using a LIV1-ADC and a chemotherapeutic

The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.

Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation

The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.

Humanized antibodies to LIV-1 and use of same to treat cancer

The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.

CD123 antibodies and conjugates thereof

The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

CD33 antibodies and use of same to treat cancer

The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.

Variant target binding agents and uses thereof

The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.

Growing community of inventors

Bothell, WA, United States of America

Django Sussman